Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone microneedling versus tuberculin syringe injection for hypertrophic burn scars
IRCT20260318068999N1Phase 3Completed
- Sponsor
- Gerash University of Medical Sciences
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of triamcinolone in Hypertrophic Scar (HS) (2 arms), sponsored by Gerash University of Medical Sciences. Primary endpoints: Injection pain experience, Scar redness and 3 more. Started May 2026; status: completed.
02
Drugs
triamcinolone
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on IRCT20260318068999N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260318068999N1.